<DOC>
	<DOCNO>NCT00634582</DOCNO>
	<brief_summary>RATIONALE : Paricalcitol may help prostate cancer cell become like normal cell , grow spread slowly . It may also stop growth tumor cell bone . PURPOSE : This phase II trial study well paricalcitol work treat patient advanced prostate cancer bone metastasis .</brief_summary>
	<brief_title>Paricalcitol Treating Patients With Advanced Prostate Cancer Bone Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - To explore relationship paricalcitol therapy marker bone formation patient androgen-refractory , advanced prostate cancer bone metastasis . Secondary - To explore relationship paricalcitol therapy marker bone resorption patient . OUTLINE : Patients receive oral paricalcitol daily 10 week absence unacceptable toxicity . Patients undergo blood sample collection periodically determine marker bone formation resorption ELISA ; parathyroid hormone ( PTH ) level immunometric assay ; prostate-specific antigen ( PSA ) level immunoassay ; 25-hydroxyvitamin D 1,25 ( OH ) _2D level radioimmunoassay . Patients also undergo bone densitometry ( DEXA scan ) baseline 10 week assess change bone strength . Quality life assess prior , , completion treatment . Questionnaires include Pain Inventory , Brief Pain Inventory , Functional Assessment Cancer Therapy-G ( FACT-G ) , Analgesic Use Diary ( Narcotic Pain Medication Logbook ) . After completion study treatment , patient follow every 6 month 1 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Inclusion : Histologically cytologically confirm advanced adenocarcinoma prostate Radiographically proven bone metastasis prostate cancer Androgen refractory disease ( include antiandrogen withdrawal ) Secondary hyperparathyroidism , define two parathyroid hormone ( PTH ) value &gt; 70 pg/mL , 14 day apart ECOG performance status 02 Leukocytes ≥ 3,000/μL Absolute neutrophil count ≥ 1,500/μL Platelets ≥ 100,000/μL Total bilirubin normal AST/ALT ≤ 2.5 time upper limit normal Creatinine clearance ≥ 60 mL/min Calcium normal 25hydroxyvitamin D ( 25OHD ) ≥ 20 ng/mL 1,25 ( OH ) _2D normal Patients serum 25OHD indicative vitamin D insufficiency eligible provide treat ergocalciferol raise 25OHD level 20 ng/mL prior paricalcitol therapy More 8 week since prior bisphosphonates More 2 week since prior palliative radiotherapy More 4 week since prior therapy No one prior taxanecontaining chemotherapy regimen metastatic disease Multiple line prior therapy hormonal agent allow Concurrent corticosteroid allow provide dose remain stable study period Exclusion : Underlying metabolic bone disease vitamin D deficiency History hypercalcemia Concurrent uncontrolled illness comorbid condition ( include psychiatric illness ) would interfere study compliance Concurrent ergocalciferol supplementation Concurrent chemotherapy hormonal therapy Concurrent investigational commercial agent malignancy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>